The ASH Impact Series is the Society’s newest educational offering, which provides free, on-demand content on key topics presented at the latest ASH annual meeting. These videos can be found on ASH’s YouTube channel, and at ASH On Demand. They are based on presentations given at the 2015 ASH Annual Meeting.
In one video, titled “HLH in Adults,” Nancy Berliner, MD, discusses the diagnosis and treatment of hemophagocytic lymphohistiocytosis (HLH) in adults, as well as the overall state of our knowledge of HLH.
In another video with content stemming from the 2015 annual meeting, Marcel Van den Brink, MD, PhD, examines ways of improving thymus function, based on the session titled “Immunological Ctrl-Alt-Del: Stem Cell Transplantation for Hematological Malignancies.”
To enable hematologists to stay current with the latest advances in the rapidly evolving disciplines of adult and pediatric hematology, including benign and malignant disorders, the ASH Self-Assessment Program (ASH®-SAP), Sixth Edition, now contains 23 peer-reviewed chapters, covering the full spectrum of hematology, including:
- Laboratory hematology and cellular therapy
- Consultative hematology
- Thrombosis and hemostasis
- Anemia, iron physiology, and iron disorders
- Myeloid diseases
- Lymphoid disorders
This latest edition features 3D animation and audio, 285 new questions in the question-and-answer book, and six separate tests that can be taken individually or together, which are worth up to 70 continuing medical education (CME) and American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) points.
Visit Hematology.org/BuyASHSAP6 to pre-order, and receive your copy and/or online access in June.
The 2016 Clinical Research Training Institute final class took place at ASH headquarters in Washington, DC, on May 5, 2016. The day was filled with presentations by the trainees and small-group breakout meetings.
Front Row (L to R): Gabriela Hobbs, MD; Emily Curran, MD; Cindy Varga, MD; Oyebimpe Adesina, MD; Kehinde Adekola, MD; Maissaa Janbain, MD; Inye Ahn, MD; Sarah Dobrozsi, MD; Joseph Mikhael, MD, Med, CRTI Co-Director.
Second Row (L to R): Ewurabena Simpson, MD; Deepakbabu Chellapandian, MD; Nasheed Hossain, MD; David Sallman, MD; Marco Ruella, MD; Armin Rashidi, MD; Jacquelyn Powers, MD; Adam Cuker, MD, MS; Allison King, MD, MPH; PhD; Sarah O’Brien, MD, MSc, CRTI Co-Director; Sarah Rutherford, MD. Back Row (L to R): Riten Kumar, MD; Matthew McKinney, MD; Patrick Reagan, MD; Taxiarchis Kourelis, MD; Kara Kelly, MD; Christopher Flowers, MD, MS; Ruben Mesa, MD
ASH regularly hosts educational webinars that feature presentations by experts in the field, cover current information on how to best diagnose and care for patients, and provide time for speakers and participants to discuss relevant issues during a question-and-answer session.
This webinar will discuss the FDA’s accelerated approval of daratumumab to treat patients with multiple myeloma who have received at least three prior treatments. Daratumumab is the first monoclonal antibody approved for treating multiple myeloma.
Date: Friday, June 17, 2016
Time: 2:30 p.m. Eastern Time
Duration: 1 hour
- Mikkael Sekeres, MD, MS, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH (Moderator)
- Nicole Gormley, MD, U.S. Food and Drug Administration, Silver Spring, MD
- Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA
This webinar will discuss the FDA approval of ixazomib in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy.
Ixazomib is the first oral proteasome inhibitor and is approved in combination with lenalidomide and dexamethasone.
Date: Wednesday, June 29, 2016
Time: 2:00 p.m. Eastern Time
Duration: 1 hour
- David P. Steensma, MD, Dana-Farber Cancer Institute, Boston, MA (Moderator)
- Alexandria Schwarsin, MD, U.S. Food and Drug Administration, Silver Spring, MD
- S. Vincent Rajkumar, MD, Mayo Clinic College of Medicine, Rochester, MN
Past ASH Webinars
Recordings of ASH Webinars are available at ASH On Demand.
Webinars recently added to ASH On Demand include:
- ASH/FDA Update on von Willebrand Factor (Recombinant): The approval of von Willebrand factor (recombinant) to treat adults 18 years of age or older who have von Willebrand disease (vWD). This is the first FDA-approved recombinant von Willebrand factor for the on-demand treatment and control of bleeding episodes in adults with vWD.
- ASH/FDA Update on Idarucizumab: The FDA accelerated approval of idarucizumab for the management of patients treated with dabigatran when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery or procedures, or in life-threatening or uncontrolled bleeding.